ArticleHarm reduction journal2022
Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Mixed-methods analysis on psychedelic-augmented meditation experiences from a randomized controlled mindfulness retreat.Scientific reports · 2026Trial
- Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.Psychopharmacology · 2025Trial
- Set and Setting for Psychedelic Harm Reduction.Current topics in behavioral neurosciences · 2026Review
- Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.Harm reduction journal · 2025Article
- Harm reduction practises for users of psychedelic drugs: a scoping review.Harm reduction journal · 2025Article
- Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms.Psychiatry and clinical psychopharmacology · 2025Article
- Welfare first: transforming harm reduction at UK festivals.Harm reduction journal · 2025Article
- Participants' Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.Frontiers in pharmacology · 2025Article
- Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- An Occupational Perspective on Psychedelic Therapy: A Scoping Review.Canadian journal of occupational therapy. Revue canadienne d'ergotherapie · 2024Article
- Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights.Journal of psychopharmacology (Oxford, England) · 2024Article
- Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.Journal of cannabis research · 2024Article
- Psychological effects of psychedelics in adolescents.Frontiers in child and adolescent psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlongside a recent revival in the use of psychedelics in clinical settings, there have been increases in the prevalence of recreational use, with many using psychedelics to deal with difficult emotions or to improve well-being. While clinical research is conducted in carefully controlled settings, this is not necessarily the case for recreational use. In this mixed methods online survey study, we aimed to develop an understanding of frequently used psychedelic harm reduction practices in recreational settings and how their use relates to the psychedelic experience. We also aimed to characterise users' first and most recent psychedelic trips to understand how harm reduction changes with experience.
methodsParticipants (n = 163) recounted their first and most recent psychedelic experience by providing details about the harm reduction practices they employed and completing the Challenging Experience Questionnaire (CEQ) and Emotional Breakthrough Inventory (EBI). We also asked open-ended questions for a more in-depth qualitative understanding of their views on psychedelic harm reduction.
resultsUsing ANOVA, we observe greater use of harm reduction practices for participants' most recent versus first psychedelic experience and that use of these practices is positively associated with EBI scores and negatively associated with CEQ scores (particularly for the first experience). Participants engaged in a wide range of harm reduction practices and we provide details of those which are most commonly used and those which are deemed most important by experienced users. Our qualitative analysis indicated that participants were largely positive about psychedelics and many recounted profound positive experiences. While specifics of the drug they were taking was important for aspects of harm reduction, participants largely focused on the importance of ensuring a good "set and setting" for enhancing positive effects.
conclusionsOur research helps us understand how engagement in harm reduction may increase with experience. Our mixed methods data shed light on the perceived importance of different harm reduction practices and examine their association with the psychedelic experience itself. Together, our research has important implications for the development of psychedelic harm reduction advice and provides opportunities for future research to explore the importance of these different practices in more detail.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.